Press Releases

---------------------------------------------------------------- FOR IMMEDIATE RELEASE

CONTACTS:	César García, President and Chief Executive Officer
	818-709-1244 x 7123
	Or
	Ron Stabiner, The Wall Street Group, Inc.
	212-888-4848

IRIS ENGAGES MED TECH ASSOCIATES TO SUPPORT SALES OF iCHEM™100 and vCHEM™ URINE CHEMISTRY PRODUCTS IN THE U.S.

CHATSWORTH, Calif., July 11, 2006 — IRIS International, Inc. (NASDAQ: IRIS) a manufacturer and marketer of automated IVD urinalysis systems and medical devices used in hospitals, clinical reference laboratories and physician office laboratories worldwide, today announced that Med Tech Associates, Inc., a professional manufacturer's representation organization with nationwide coverage, will provide field-level product sales support activities in the United States. Med Tech's 29 representatives will act as domestic sales agents of Iris Diagnostics, supporting sales activities for the new urine chemistry product lines in a coordinated effort with a recently established distribution network consisting of most major medical device distributors in the U.S.

"Med Tech is regarded as having one of the strongest independent sales forces in the United States, representing some of the leading companies in the medical device field," stated IRIS President and Chief Executive Officer César García. "Under the agreement, Med Tech will focus on commercializing IRIS' new iChem™100 Urine Chemistry Analyzer and Test Strips and the vChem™ line of visual-read Test Strips, which are specifically designed for smaller hospitals, outpatient clinics and physicians' offices. This is the first time IRIS will sell specific Iris Diagnostics' products through third-party distributors. We will concentrate their efforts on selling the iChem and vChem products exclusively in market segments which are new to IRIS and not currently addressed by our direct sales force. Our partnership with Med Tech is the first of a number of sales and marketing initiatives the Company is planning for showcasing and increasing industry awareness of our new product lines and to enhance our domestic distribution coverage."

Iris Diagnostics President Dino Alfano noted that IRIS' Diagnostics Division is committed to becoming a key player in the urine chemistry market. "Med Tech will provide us with the competitive and distribution expertise, as well as the sales support infrastructure necessary to assist in completing the sale of our products in the U.S.," he stated. "MedTech's representatives will interface directly with our distributors in the sales and demonstration process, highlighting the advantages of our iChem and vChem products in front of potential customers."

The iChem100 will be officially launched at the American Association of Clinical Chemistry's (AACC) annual meeting in Chicago on July 23-27.

In June 2006, the U.S. Food and Drug Administration granted 510(k) clearance for the iChem100, a semi-automated urine chemistry analyzer and related test strips, designed for low to mid-volume hospital laboratories, outpatient clinics and large physicians offices. The iChem100, which will be marketed by IRIS' distributors in the U.S. and overseas, addresses a target market of an estimated 8,000 sites globally. The vChem visual-read test strips will be marketed and sold to lower volume physician office laboratories.

IRIS International, a leading manufacturer in the urine microscopy market with its iQ^®200 Automated Urine Microscopy Analyzers and Systems, is rounding out its own branded product line by entering the $350 million urine chemistry market. The Company also plans to launch a fully automated chemistry analyzer in the second half of 2007 to address markets currently not served by IRIS.

About Med Tech Associates, Inc.

Med Tech Associates (MTA), a private company based in Idaho Springs, Colo., is an independent sales organization serving the healthcare industry. Med Tech contracts with manufacturers of medical products and devices to act as their field sales agents, who primarily work with companies which market their products through physician and hospital suppliers.

The Company

IRIS International, Inc. (http://www.proiris.com), based in Chatsworth, Calif., is a leader in automated urinalysis technology with systems in major medical institutions throughout the world. The Company's Sample Processing business unit (formerly the StatSpin^® subsidiary) (www.statspin.com), based in Westwood, Mass., manufactures innovative centrifuges and blood analysis products. Advanced Digital Imaging Research, LLC (ADIR) (www.adires.com), based near Houston, Texas, is the Company's imaging research and development subsidiary. The IRIS Molecular Diagnostics (IMD) Subsidiary develops innovative ultra-sensitive diagnostics and sample processing products with applications in the urinalysis, oncology and infectious disease markets.

SAFE HARBOR PROVISION

This news release contains forward-looking statements made in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, the Company's views on future financial performance, market growth, capital requirements, new product introductions and acquisitions, and are generally identified by phrases such as "thinks," "anticipates," "believes," "estimates," "expects," "intends," "plans," and similar words. Forward-looking statements are not guarantees of future performance and are inherently subject to uncertainties and other factors which could cause actual results to differ materially from the forward-looking statement. These statements are based upon, among other things, assumptions made by, and information currently available to, management, including management's own knowledge and assessment of the Company's industry, R&D initiatives, competition and capital requirements. Other factors and uncertainties that could affect the Company's forward-looking statements include, among other things, the following: identification of feasible new product initiatives, management of R&D efforts and the resulting successful development of new products and product platforms; acceptance by customers of the Company's products; integration of acquired businesses; substantial expansion of international sales; reliance on key suppliers; the potential need for changes in long-term strategy in response to future developments; future advances in diagnostic testing methods and procedures; potential changes in government regulations and healthcare policies, both of which could adversely affect the economics of the diagnostic testing procedures automated by the Company's products; rapid technological change in the microelectronics and software industries; and competitive factors, including pricing pressures and the introduction by others of new products with similar or better functionality than our products. These and other risks are more fully described in the Company's filings with the Securities and Exchange Commission, including the Company's most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q, which should be read in conjunction herewith for a further discussion of important factors that could cause actual results to differ materially from those in the forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.